ESMO 2018 | Future therapeutic strategies for HCC

Arndt Vogel, MD, PhD, of Hannover Medical School, Hannover, Germany, discusses combination therapies, particularly immuno agents plus local therapy, for the future of hepatocellular carcinoma (HCC) treatment. Prof. Vogel suggests that immunotherapy could enhance the response of HCC patients who receive local or systemic therapy. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.